Rein Therapeutics, Inc. Financials
This page shows Rein Therapeutics, Inc. (RNTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rein Therapeutics is still a cash-burn business funded mainly by equity issuance, and liquidity has tightened faster than leverage has risen.
Over the last three fiscal years, operating cash burn stayed close to-$20M annually even as net loss ballooned to-$49.9M , meaning reported losses became a poor proxy for actual cash use. With cash at$3.2M and the current ratio at 0.7x, near-term funding needs are now being set by liquidity rather than leverage.
The balance sheet is still lightly levered: liabilities were only
By the latest year, R&D and SG&A were both about
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Rein Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Rein Therapeutics, Inc. carries a low D/E ratio of 0.43, meaning only $0.43 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.
Rein Therapeutics, Inc.'s current ratio of 0.70 is below the typical benchmark, resulting in a score of 9/100. However, the company holds substantial cash reserves (52% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Rein Therapeutics, Inc. generates a -294.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -115.6% the prior year.
Rein Therapeutics, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Rein Therapeutics, Inc. generates $0.39 in operating cash flow (-$19.4M OCF vs -$49.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Rein Therapeutics, Inc. generated $0 in revenue in fiscal year 2025.
Rein Therapeutics, Inc.'s EBITDA was -$50.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.2% from the prior year.
Rein Therapeutics, Inc. reported -$49.9M in net income in fiscal year 2025. This represents an increase of 20.7% from the prior year.
Rein Therapeutics, Inc. earned $-1.96 per diluted share (EPS) in fiscal year 2025. This represents an increase of 44.2% from the prior year.
Cash & Balance Sheet
Rein Therapeutics, Inc. held $3.2M in cash against $0 in long-term debt as of fiscal year 2025.
Rein Therapeutics, Inc. paid $0.00 per share in dividends in fiscal year 2025.
Rein Therapeutics, Inc. had 28M shares outstanding in fiscal year 2025. This represents an increase of 27.2% from the prior year.
Margins & Returns
Rein Therapeutics, Inc.'s ROE was -294.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 179.2 percentage points from the prior year.
Capital Allocation
Rein Therapeutics, Inc. invested $11.0M in research and development in fiscal year 2025. This represents a decrease of 22.6% from the prior year.
RNTX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $1.7M-60.8% | $4.3M+40.5% | $3.1M | N/A | $3.7M-0.5% | $3.7M+8.0% | $3.5M |
| SG&A Expenses | N/A | $3.8M+47.8% | $2.6M+0.9% | $2.6M | N/A | $2.3M-55.7% | $5.3M+41.6% | $3.7M |
| Operating Income | N/A | -$5.5M+20.1% | -$6.9M-22.5% | -$5.6M | N/A | -$6.1M+32.8% | -$9.0M-25.5% | -$7.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$5.6M+18.2% | -$6.8M-24.0% | -$5.5M | N/A | -$5.8M+34.6% | -$8.9M-25.7% | -$7.1M |
| EPS (Diluted) | N/A | $-0.21+25.0% | $-0.28-12.0% | $-0.25 | N/A | $-0.27+40.0% | $-0.45+47.7% | $-0.86 |
RNTX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $24.2M-55.0% | $53.7M-6.6% | $57.5M-0.3% | $57.6M-7.3% | $62.2M-40.3% | $104.2M-4.7% | $109.4M+10.3% | $99.2M |
| Current Assets | $4.3M-16.4% | $5.2M-21.6% | $6.6M-20.8% | $8.3M-39.0% | $13.7M-26.9% | $18.7M-19.3% | $23.2M+81.4% | $12.8M |
| Cash & Equivalents | $3.2M-20.6% | $4.0M-29.3% | $5.7M-23.0% | $7.4M-42.3% | $12.9M-27.1% | $17.7M-19.5% | $21.9M+82.0% | $12.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M0.0% | $6.3M |
| Total Liabilities | $7.2M-3.7% | $7.5M-20.6% | $9.5M+22.2% | $7.7M-0.6% | $7.8M-13.2% | $9.0M+7.2% | $8.4M+6.6% | $7.9M |
| Current Liabilities | $6.2M+7.6% | $5.7M-25.3% | $7.7M+28.7% | $6.0M+4.0% | $5.7M+1.6% | $5.7M+14.6% | $4.9M+8.9% | $4.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $16.9M-63.4% | $46.2M-3.8% | $48.0M-3.7% | $49.9M-8.3% | $54.4M-42.9% | $95.2M-5.7% | $101.0M+10.6% | $91.3M |
| Retained Earnings | -$401.3M-8.7% | -$369.3M-1.5% | -$363.7M-1.9% | -$356.9M-1.6% | -$351.4M-13.2% | -$310.4M-1.9% | -$304.6M-3.0% | -$295.6M |
RNTX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M+9.2% | -$3.5M+44.7% | -$6.4M-3.9% | -$6.2M-28.3% | -$4.8M-26.0% | -$3.8M+54.5% | -$8.4M-59.2% | -$5.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $2.4M+26.6% | $1.9M-59.7% | $4.7M+538.5% | $738K+73700.0% | $1K+100.2% | -$446K-102.4% | $18.3M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RNTX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -12.1%+2.1pp | -14.2%-3.2pp | -11.0% | N/A | -6.1%+2.7pp | -8.8%-1.1pp | -7.8% |
| Return on Assets | N/A | -10.4%+1.5pp | -11.9%-2.3pp | -9.6% | N/A | -5.6%+2.6pp | -8.2%-1.0pp | -7.2% |
| Current Ratio | 0.70-0.2 | 0.90+0.0 | 0.86-0.5 | 1.39-1.0 | 2.38-0.9 | 3.30-1.4 | 4.69+1.9 | 2.82 |
| Debt-to-Equity | 0.43+0.3 | 0.16-0.0 | 0.20+0.0 | 0.16+0.0 | 0.14+0.0 | 0.09+0.0 | 0.080.0 | 0.09 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.70), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Rein Therapeutics, Inc.'s annual revenue?
Rein Therapeutics, Inc. (RNTX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Rein Therapeutics, Inc. profitable?
No, Rein Therapeutics, Inc. (RNTX) reported a net income of -$49.9M in fiscal year 2025.
What is Rein Therapeutics, Inc.'s EBITDA?
Rein Therapeutics, Inc. (RNTX) had EBITDA of -$50.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rein Therapeutics, Inc.'s return on equity (ROE)?
Rein Therapeutics, Inc. (RNTX) has a return on equity of -294.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rein Therapeutics, Inc.'s operating cash flow?
Rein Therapeutics, Inc. (RNTX) generated -$19.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Rein Therapeutics, Inc.'s total assets?
Rein Therapeutics, Inc. (RNTX) had $24.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Rein Therapeutics, Inc. spend on research and development?
Rein Therapeutics, Inc. (RNTX) invested $11.0M in research and development during fiscal year 2025.
What is Rein Therapeutics, Inc.'s current ratio?
Rein Therapeutics, Inc. (RNTX) had a current ratio of 0.70 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Rein Therapeutics, Inc.'s debt-to-equity ratio?
Rein Therapeutics, Inc. (RNTX) had a debt-to-equity ratio of 0.43 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rein Therapeutics, Inc.'s return on assets (ROA)?
Rein Therapeutics, Inc. (RNTX) had a return on assets of -206.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rein Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Rein Therapeutics, Inc. (RNTX) had $3.2M in cash against an annual operating cash burn of $19.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rein Therapeutics, Inc.'s Piotroski F-Score?
Rein Therapeutics, Inc. (RNTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rein Therapeutics, Inc.'s earnings high quality?
Rein Therapeutics, Inc. (RNTX) has an earnings quality ratio of 0.39x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Rein Therapeutics, Inc.?
Rein Therapeutics, Inc. (RNTX) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.